{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Germany Drug Manufacturers - General news", "home_page_url": "https://sharemaestro.com/newsreel/de/healthcare/drug-manufacturers-general/", "feed_url": "https://sharemaestro.com/newsreel/de/healthcare/drug-manufacturers-general/feed.json", "description": "Latest Drug Manufacturers - General company headlines from Germany, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:6f3ad19d45a6717c24f32fbbfc13925fbc5ddd56cad0c94e00daaf0deab9b172", "url": "https://finance.yahoo.com/markets/stocks/articles/amgen-amgn-stock-looks-undervalued-120946360.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/amgen-amgn-stock-looks-undervalued-120946360.html", "title": "Amgen (AMGN) Stock Looks Undervalued With A 37% Fair Value Gap", "content_text": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Amgen stock has delivered strong gains over the past five years, yet the current share price sits at a discount to an intrinsic value estimate based on a Discounted Cash Flow (DCF) model, while broader valuation checks point to a more mixed picture. Amgen has returned 116.3% over the past five years, which puts more weight on whether the current valuation still leaves room for an attractive long term outcome. Plans to open a", "date_published": "2026-08-14T12:09:46+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "AMG"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "AMG", "name": "Amgen Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/168fd802-fccc-4e50-a2bc-bc539b6e35a1/"}]}}, {"id": "source:ac904f1c46ae1d07a76c2eb67def2f0c2e33c3bdf87a7858ec6a336d1dc5211f", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQbEl3NjBGUHVWaXh5djVmMUlYNU9OYkNjbzB2SHdtTjBFYUpIMGR3WVV4YlF1TTVHTkF2eDhrV1h5TVpuYWloSmRkcWtYNDczdThSOVlYV1p6M0ZWczhFcDdtNTZoMDZhZHlobGo2ZEhmZlNTMTRiV2ZkcFlZeUpLa1RvcVNQbmNwZ3lIQ3ZueW82QVpVLTROaUFta054ejhRZWZNZXA2TDZic1lGWmFiemJmZFpDY3phc0tUcHdfUzBBMDZ5T0hXQ1BDTQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQbEl3NjBGUHVWaXh5djVmMUlYNU9OYkNjbzB2SHdtTjBFYUpIMGR3WVV4YlF1TTVHTkF2eDhrV1h5TVpuYWloSmRkcWtYNDczdThSOVlYV1p6M0ZWczhFcDdtNTZoMDZhZHlobGo2ZEhmZlNTMTRiV2ZkcFlZeUpLa1RvcVNQbmNwZ3lIQ3ZueW82QVpVLTROaUFta054ejhRZWZNZXA2TDZic1lGWmFiemJmZFpDY3phc0tUcHdfUzBBMDZ5T0hXQ1BDTQ?oc=5", "title": "Die Bristol-Myers-Squibb-Aktie legt nach starken Q2-Zahlen und neuer Zahlung zu", "content_text": "Die Bristol-Myers-Squibb-Aktie legt nach starken Q2-Zahlen und neuer Zahlung zu", "date_published": "2026-08-14T11:43:53+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Market update", "BRM"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BRM", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/76da2cf7-50cc-4dc4-b51d-157448b7cb97/"}]}}, {"id": "source:e6793ea00b43a8209175c2cdffd939d23887d050c43a1a645355d97124e49d99", "url": "https://www.nasdaq.com/articles/fidelity-healthcare-etf-vs-ishares-pharma-fund-which-wins", "external_url": "https://www.nasdaq.com/articles/fidelity-healthcare-etf-vs-ishares-pharma-fund-which-wins", "title": "Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins?", "content_text": "Key Points Fidelity MSCI Health Care Index ETF offers a lower expense ratio of 0.08% compared to the 0.37% fee for iShares U.S. Pharmaceuticals ETF. iShares' fund provides concentrated exposure to 56 pharmaceutical stocks, while Fidelity's holds 338 stocks across the broader healthcare sector. The iShares fund delivered a higher one-year total return of 60% as of Aug. 10, 2026.10 stocks we like better than Fidelity Covington Trust - Fidelity Msci Health Care Index ETF \u203a While Fidelity MSCI Health Care Index ETF(NYSEMKT:FHLC) provides broad healthcare exposure at a very low cost, iShares U.S. P", "date_published": "2026-08-14T11:35:01+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Market update", "BRM"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BRM", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/76da2cf7-50cc-4dc4-b51d-157448b7cb97/"}]}}, {"id": "source:4a3743dd6463ed105ffc9c1441902f440c6c025c3c9d0aedf7bd19fa086ad557", "url": "https://finance.yahoo.com/healthcare/articles/amgen-amgn-opens-science-innovation-111231819.html", "external_url": "https://finance.yahoo.com/healthcare/articles/amgen-amgn-opens-science-innovation-111231819.html", "title": "Amgen (AMGN) Opens New Science And Innovation Center In Hyderabad", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Amgen (NasdaqGS:AMGN) announced the opening of a new Science and Innovation Center in Genome Valley, Hyderabad, expanding its global research and development presence. The Hyderabad center is designed to integrate scientific capabilities with data and digital tools to support discovery and development of new medicines. This expansion adds another research hub to Amgen's global footprint and increases its geographic diversification in Asia. Amgen is not the only healthcare stock investing", "date_published": "2026-08-14T11:12:31+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "AMG"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "AMG", "name": "Amgen Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/168fd802-fccc-4e50-a2bc-bc539b6e35a1/"}]}}, {"id": "source:b8949dc9667dcce383f343bbc7bf9b59ebcb2d5d88a8a384fafd3899095259d3", "url": "https://www.nasdaq.com/articles/schd-vs-hdv-which-dividend-etf-better-buy-investors", "external_url": "https://www.nasdaq.com/articles/schd-vs-hdv-which-dividend-etf-better-buy-investors", "title": "SCHD vs. HDV: Which Dividend ETF Is the Better Buy for Investors?", "content_text": "Key Points The Schwab U.S. Dividend Equity ETF (SCHD) offers a slightly lower expense ratio and stronger recent returns than the iShares Core High Dividend ETF (HDV). HDV maintains a modestly more concentrated portfolio, with 75 holdings compared to SCHD's 103. Over the past five years, HDV has posted both stronger total returns and a less severe maximum drawdown than SCHD.10 stocks we like better than Schwab U.S. Dividend Equity ETF \u203a Income-seeking investors often gravitate toward established dividend funds to balance long-term capital appreciation with steady quarterly cash flow. Both the S", "date_published": "2026-08-14T11:11:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Capital return", "AMG"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "AMG", "name": "Amgen Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/168fd802-fccc-4e50-a2bc-bc539b6e35a1/"}]}}, {"id": "source:e142f91199ddc701efe333aa5e8027026f2517e3c090202450a3265d89e820a2", "url": "https://finance.yahoo.com/markets/stocks/articles/bekaert-share-buyback-program-liquidity-061500238.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/bekaert-share-buyback-program-liquidity-061500238.html", "title": "Bekaert: Update on the Share Buyback Program and the Liquidity Agreement", "content_text": "Bekaert Update on the Share Buyback Program and the Liquidity Agreement Period from 6 August 2026 to 12 August 2026 Share Buyback Program On 26 February 2026, Bekaert announced the start of the next tranche of its share buyback program, for a total maximum consideration of up to \u20ac 75 million. As announced previously, the purpose of the Program is to cancel all shares repurchased. Bekaert announces today that during the period from 6 August 2026 to 12 August 2026, Kepler Cheuvreux SA on behalf of Bekaert has bought 56 000 shares. The table below provides an overview of the transactions under th", "date_published": "2026-08-14T06:15:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "BAYN"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BAYN", "name": "Bayer Aktiengesellschaft", "sentiment_url": "https://sharemaestro.com/sentiment/51239ea0-c40c-4626-8574-e77021366c47/"}]}}, {"id": "source:628df1dfc51b43eaf5176f665aa8074ea9d077a0712fc5bd8d80d1a4d67c31c5", "url": "https://finance.yahoo.com/markets/stocks/articles/afarak-group-interim-report-h1-060000892.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/afarak-group-interim-report-h1-060000892.html", "title": "AFARAK GROUP: INTERIM REPORT H1 2026", "content_text": "Afarak Group SE 07:00 London, 09:00 Helsinki, 14 August 2026 - Afarak Group SE (\"Afarak\" or \"the Company\") (LSE: AFRK, NASDAQ: AFAGR) FINANCIAL INTERIM RELEASE H1 2026 H1/26 H1/25 2025 Revenue EUR million 57.1 77.1 141.3 EBITDA EUR million 1.6 6.9 -0.2 EBIT EUR million 0.5 5.9 -2.6 Earnings before taxes EUR million 0.1 3.4 -7.5 (Loss) / Profit for the period EUR million -0.7 2.4 -8.9 Earnings per share EUR 0.00 0.01 -0.03 EBITDA margin 2.8% 9.0% -0.2 EBIT margin 0.8% 7.7% -1.8 Earnings margin 0.2% 4.5% -5.3 Personnel (end of period) 625 613 626 FIRST HALF 2026 HIGHLIGHTS The Group recorded an ", "date_published": "2026-08-14T06:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BAYN"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BAYN", "name": "Bayer Aktiengesellschaft", "sentiment_url": "https://sharemaestro.com/sentiment/51239ea0-c40c-4626-8574-e77021366c47/"}]}}, {"id": "source:0900c281a1b7e54999dfd196bbfe90a2a2a5cb52fdbe999e1d2a91793c625390", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-valneva-lyme-disease-vaccine-050000585.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizer-valneva-lyme-disease-vaccine-050000585.html", "title": "Pfizer and Valneva\u2019s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency", "content_text": "Submission based on favorable efficacy and safety results from Phase 3 VALOR trial NEW YORK & LYON, France, August 14, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies' 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application. The application is based on encouraging efficacy of more than 70% observed in the Phase 3 VALOR \"Vaccine Ag", "date_published": "2026-08-14T05:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b7ca93f2-2dc7-4008-a388-6f2d93608932/"}]}}, {"id": "source:73f203305b5d54485de2deb2823ca9b04af33338a782dd1b173d26623ce497c7", "url": "https://www.nasdaq.com/articles/reported-400-billion-astrazeneca-bristol-myers-squibb-megamerger-slam-dunk-or-disaster", "external_url": "https://www.nasdaq.com/articles/reported-400-billion-astrazeneca-bristol-myers-squibb-megamerger-slam-dunk-or-disaster", "title": "Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?", "content_text": "Key Points Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if on paper such a deal would create an oncology-focused big pharma powerhouse worth around $400 billion. Considering regulatory uncertainty and other negatives, it makes sense why Wall Street isn't liking these merger rumors.10 stocks we like better than Bristol Myers Squibb \u203a In recent weeks, two pharmaceutical stocks, AstraZeneca(NYSE: AZN) and Bristol Myers Squibb(NYSE: BMY), have become the subject of merger rumors. At the start of the m", "date_published": "2026-08-14T02:20:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Deals and strategy", "BRM"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BRM", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/76da2cf7-50cc-4dc4-b51d-157448b7cb97/"}]}}, {"id": "source:e9910ce59642be6aa999514f06aedcc53452cf2fd331fe433b68b6c9c6898454", "url": "https://finance.yahoo.com/markets/stocks/articles/mlp-se-wbo-mlp-q2-230932085.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/mlp-se-wbo-mlp-q2-230932085.html", "title": "MLP SE (WBO:MLP) (Q2 2026) Earnings Call Highlights: Record Revenue and EBIT Fuel Optimistic Outlook", "content_text": "This article first appeared on GuruFocus. Total Revenue: Increased by 10% to a record EUR583 million in the first half of 2026. EBIT: Reached a new record high of EUR64 million in the first half of 2026. Revenue by Competence Field: Property & Casualty grew 12%, Wealth grew 11%, and Life & Health was slightly above the previous year's levels. Assets Under Management: Increased to a new record level of EUR68.8 billion. Non-life Insurance Premium Volume: Reached a new record high of EUR865 million. Equity: Increased from EUR585 million to EUR589 million compared to the 2025 balance sheet date. R", "date_published": "2026-08-13T23:09:32+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BAYN"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BAYN", "name": "Bayer Aktiengesellschaft", "sentiment_url": "https://sharemaestro.com/sentiment/51239ea0-c40c-4626-8574-e77021366c47/"}]}}, {"id": "source:c3a98a5f8747a521982b0d128ec0396d98d710f52be0af746179603a914f830a", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-5-5b-230726728.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-jnj-5-5b-230726728.html", "title": "Johnson & Johnson (JNJ)\u2019s $5.5B Talc Settlement: Turning Point or Temporary Relief?", "content_text": "The World Health Organization projects that the share of the world's population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from 58 million in 2022 to 82 million by 2050. The aging population is fueling demand for healthcare. US healthcare spending is forecast to hit $6 trillion in 2026 from $5.7 trillion in 2025. This trend reflects an expanding market for medical products companies. Yet for large healthcare companies, legal issues can erode the benefits of favorable mark", "date_published": "2026-08-13T23:07:26+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "JNJ"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/e87ae051-5953-43aa-97e5-132814dcdeea/"}]}}, {"id": "source:43fb835313f01faeda6bcafaf7ebbaf8394c86b41d24f6a7ca130156aae1ed4f", "url": "https://finance.yahoo.com/healthcare/articles/could-gsk-plc-gsk-pipeline-220109388.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-gsk-plc-gsk-pipeline-220109388.html", "title": "Could GSK plc (GSK)\u2019s Pipeline Acceleration Unlock a New Growth Era?", "content_text": "On July 28, GSK plc (NYSE:GSK) reported its second-quarter financial results, delivering strong core operational performance and showcasing steady commercial momentum. The firm's total Q2 turnover reached \u00a38.4 billion, marking a 5% increase year-over-year at constant exchange rates (CER), while Core operating profit climbed 7% CER to \u00a32.80 billion and Core EPS rose 9% CER to 50.5p. Growth was primarily fueled by double-digit gains in Specialty Medicines (+14% CER to \u00a33.8 billion) and robust momentum in Vaccines (+8% CER to \u00a32.3 billion). However, Total operating profit dropped 75% CER to \u00a3481 ", "date_published": "2026-08-13T22:01:09+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GS71"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GS71", "name": "GSK plc", "sentiment_url": "https://sharemaestro.com/sentiment/067e7168-cebe-45f9-8666-2b4a34da7f50/"}]}}, {"id": "source:fc6f9ec80ab7f72145e43545e812f5b77553f112e9ad3ad2c9cb1395394825e5", "url": "https://finance.yahoo.com/healthcare/articles/could-merck-co-inc-mrk-214608790.html", "external_url": "https://finance.yahoo.com/healthcare/articles/could-merck-co-inc-mrk-214608790.html", "title": "Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)\u2019s Partnership Create the Next Big Pharma Growth Engine", "content_text": "Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn't always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this year, their recent double dose of clinical and regulatory breakthroughs across oncology and virology shows how strategic alliances can reshape two massive therapeutic markets at once.Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)\u2019s Partnership Create the Next Big Pharma Growth", "date_published": "2026-08-13T21:46:08+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GIS"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GIS", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e3c6982e-ae5c-4ff3-adc6-34eca37512f0/"}]}}, {"id": "source:b86a19034e00afa9d2e6cf46ad3ac437d2c17839da92b496fd0c18240c6c4e29", "url": "https://finance.yahoo.com/healthcare/articles/u-fda-grants-accelerated-approval-211200307.html", "external_url": "https://finance.yahoo.com/healthcare/articles/u-fda-grants-accelerated-approval-211200307.html", "title": "U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS\u2122, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse", "content_text": "Product Image (Photo: Bristol Myers Squibb)ZENBEXUS\u2122 (iberdomide) Logo Approval based on EXCALIBER-RRMM results showing ZDd doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone (41% vs. 21%) in relapsed or refractory multiple myeloma(1) ZENBEXUS marks the arrival of a new treatment class, representing the next chapter in Bristol Myers Squibb's targeted protein degradation platform PRINCETON, N.J., August 13, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has a", "date_published": "2026-08-13T21:12:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BRM"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BRM", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/76da2cf7-50cc-4dc4-b51d-157448b7cb97/"}]}}, {"id": "source:97abb1479c491d8ba318966da99fb82d37b173bee51f2fb9b122d1e372a8b78a", "url": "https://finance.yahoo.com/healthcare/articles/atrium-therapeutics-reports-second-quarter-204400492.html", "external_url": "https://finance.yahoo.com/healthcare/articles/atrium-therapeutics-reports-second-quarter-204400492.html", "title": "Atrium Therapeutics Reports Second Quarter 2026 Financial Results", "content_text": "-- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb -- SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (\"Atrium,\" \"Atrium Therapeutics,\" or the \"Company\"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate progress including FDA clearance of its Inv", "date_published": "2026-08-13T20:44:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BRM"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BRM", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/76da2cf7-50cc-4dc4-b51d-157448b7cb97/"}]}}, {"id": "source:0307dd02aa0975f7f8405c50db19c72c2cdf264792b461807601c006f7de5fed", "url": "https://finance.yahoo.com/healthcare/articles/assembly-biosciences-reports-second-quarter-200000615.html", "external_url": "https://finance.yahoo.com/healthcare/articles/assembly-biosciences-reports-second-quarter-200000615.html", "title": "Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates", "content_text": "Assembly Biosciences, Inc. \u2013 Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) \u2013 \u2013 Completed $115 million gross financing to support advancement of pipeline programs through key development milestones \u2013 \u2013 GS-1179 (formerly ABI-1179) selected to advance in HSV HPI program, with Phase 2 initiation expected by year-end 2026 \u2013 \u2013 Cash runway projected into 2029, including first $75 million Gilead collaboration extension payment due in Q4 2026 \u2013 SOUTH SAN FRANCISCO, Calif., Aug. 13, 2026 (GLOBE", "date_published": "2026-08-13T20:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "GIS"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GIS", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e3c6982e-ae5c-4ff3-adc6-34eca37512f0/"}]}}, {"id": "source:0f4f9816ac288bbbdb5a400fe337aa24cdb4d2657cfc0feb0472fa5db9f39220", "url": "https://finance.yahoo.com/healthcare/articles/gene-therapy-remains-top-mind-185900886.html", "external_url": "https://finance.yahoo.com/healthcare/articles/gene-therapy-remains-top-mind-185900886.html", "title": "Gene Therapy Remains Top-of-Mind in Hemophilia Despite Recent Market Contraction, as Physicians and Patients Raise the Bar for Success", "content_text": "Nearly nine in ten EU4+UK hematologists now require longer-term efficacy data before referring patients with hemophilia A for gene therapy, while Spherix patient research reveals continued interest in the modality. Exton, PA, Aug. 13, 2026 (GLOBE NEWSWIRE) -- The hemophilia gene therapy market is contracting commercially, but physician and patient interest in the modality has not disappeared. Recent commercial developments, including the discontinuation of BEQVEZ\u00ae (Pfizer), withdrawal of ROCTAVIAN\u00ae (BioMarin), and supply challenges for HEMGENIX\u00ae (CSL Behring), have narrowed the available gene ", "date_published": "2026-08-13T18:59:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Macro sensitivity", "PFE"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b7ca93f2-2dc7-4008-a388-6f2d93608932/"}]}}, {"id": "source:69a4a7c7fbad651b7d48f5808fc27680e8ea0f4e38147e36a268caab830e0e29", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-slips-pill-183832098.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-slips-pill-183832098.html", "title": "Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race", "content_text": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped approximately 1% Thursday morning as CEO Mike Doustdar tried to reset the market's thinking about the obesity race. His pitch: stop treating Novo versus Eli Lilly (NYSE:LLY) like a winner-takes-all fight. The obesity market could top $100 billion annually by 2030, and different patients will want different drugs, delivery methods and trade-offs. For Novo, that is more than a talking point. It is the heart of the comeback story after Lilly's Zepbound grabbed moment", "date_published": "2026-08-13T18:38:32+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOV", "LLY"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOV", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/99663662-e62d-4669-8f9e-ac0c78084f2f/"}, {"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/6ac19f25-d335-40a8-b326-861b94ed8006/"}]}}, {"id": "source:a037eecd9aac32645ee2d0d31d4fd7f24611ea1ba15b64b64008f2e6918df676", "url": "https://finance.yahoo.com/markets/stocks/articles/investors-buy-wst-hvp-growth-174800264.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/investors-buy-wst-hvp-growth-174800264.html", "title": "Should Investors Buy WST as HVP Growth Meets a Premium Valuation?", "content_text": "West Pharmaceutical Services, Inc. WST is delivering faster High-Value Product (HVP) growth, wider margins and higher 2026 earnings expectations. Second-quarter organic sales rose 12.7%, while adjusted earnings increased 28.8% to $2.37 per share. The question is whether those gains justify a valuation well above industry levels. WST's growth drivers remain attractive, but the premium multiple leaves less room for operational missteps. WST's HVP Growth Supports the Bull Case HVP Components generated $424.1 million in second-quarter sales, or 49% of total company revenues, and grew 18.4% organic", "date_published": "2026-08-13T17:48:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLY"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/6ac19f25-d335-40a8-b326-861b94ed8006/"}]}}, {"id": "source:d2b8070a7f11de2bcc7d266e2f82a94fb7c534645525c7d5d6d1821803b2ad18", "url": "https://finance.yahoo.com/healthcare/articles/wst-q2-beat-raised-2026-174800503.html", "external_url": "https://finance.yahoo.com/healthcare/articles/wst-q2-beat-raised-2026-174800503.html", "title": "WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story", "content_text": "West Pharmaceutical Services, Inc. WST turned a better-than-expected second quarter into a higher 2026 outlook. Organic sales growth accelerated, margins widened and adjusted earnings increased sharply, giving investors a clearer read on how High-Value Product demand is translating into financial performance. The quarter matters because the guidance increase was supported by broad HVP momentum rather than a single product line. Execution risks remain in West Vantage and the SmartDose transition, but the earnings trajectory improved. WST's Q2 Beat Resets 2026 Expectations Adjusted earnings rose", "date_published": "2026-08-13T17:48:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLY"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/6ac19f25-d335-40a8-b326-861b94ed8006/"}]}}, {"id": "source:9d26d0c671e6b52bc88015349553cd3b7d1b648cb07b94a61c041492b2d92917", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-escalates-weight-loss-173227558.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-escalates-weight-loss-173227558.html", "title": "Novo Nordisk Escalates Weight-Loss War With Eli Lilly", "content_text": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO) CEO Mike Doustdar is defending the drugmaker's lawsuit against Eli Lilly (NYSE:LLY), escalating a fight over how the two companies market their blockbuster obesity treatments. The legal battle matters because Lilly has seized the lead in the U.S. obesity-drug market, raising the stakes for Novo as it tries to narrow the efficacy gap consumers may perceive between Wegovy and Zepbound. Is LLY fairly valued? Test your thesis with our free DCF calculator. Novo Nordisk develops treatments for diabetes, obesity and other chronic disea", "date_published": "2026-08-13T17:32:27+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "LLY"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/6ac19f25-d335-40a8-b326-861b94ed8006/"}]}}, {"id": "source:b40ec17efd7608a9b538f7a45f663802bba7284e20cc8d0232feee1d3f8ceb2d", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisks-wegovy-fueled-rebound-172000772.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisks-wegovy-fueled-rebound-172000772.html", "title": "Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?", "content_text": "Novo Nordisk (NYSE: NVO) posted strong first-quarter results and performed fairly well in the month that followed its first-quarter update. However, the company's most recent financial update, for the second quarter, erased much of those gains. In both cases, the market's reaction was largely driven by the performance of the Wegovy pill, the first oral GLP-1 approved for weight loss, which Novo Nordisk launched in the U.S. in January. The Wegovy pill beat expectations in the first quarter but came up short in the second. What does this mean for the company's prospects?Image source: The Motley ", "date_published": "2026-08-13T17:20:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "NOV", "LLY"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOV", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/99663662-e62d-4669-8f9e-ac0c78084f2f/"}, {"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/6ac19f25-d335-40a8-b326-861b94ed8006/"}]}}, {"id": "source:9ffe2c00b2a37cdcea4a80a976a9d7e6f8e3a809762571c555c7e62d96d599f7", "url": "https://finance.yahoo.com/markets/stocks/articles/gilead-gild-stock-still-looks-171104446.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/gilead-gild-stock-still-looks-171104446.html", "title": "Gilead (GILD) Stock Still Looks Cheap On Sales Despite A 127% Run", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences stock has delivered a 126.6% total return over the past 5 years, and the current valuation checks still lean on the cheap side rather than pointing to an obvious premium. With that backdrop, investors are weighing whether the recent share price around US$135.87 already reflects the key drivers that have supported the move. A 126.6% return over 5 years suggests Gilead Sciences has rewarded long term holders, so the question is how much of ", "date_published": "2026-08-13T17:11:04+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Balance sheet", "GIS"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GIS", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e3c6982e-ae5c-4ff3-adc6-34eca37512f0/"}]}}, {"id": "source:fa1625d52811a8c2cdf68e6ccbcfdc979c1b312f424d65b9933a6954890be256", "url": "https://finance.yahoo.com/markets/stocks/articles/sanofi-information-concerning-total-number-163400000.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/sanofi-information-concerning-total-number-163400000.html", "title": "Sanofi: Information concerning the total number of voting rights and shares - July 2026", "content_text": "Sanofi Winthrop Industrie Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the R\u00e8glement g\u00e9n\u00e9ral de l'Autorit\u00e9 des March\u00e9s Financiers (Regulation of the French stock market authority) Sanofi a French soci\u00e9t\u00e9 anonyme with a registered share capital of \u20ac2,415,546,786 Registered office : 46, avenue de la Grande Arm\u00e9e - 75017 Paris - France Registered at the Paris Commercial and Companies Registry under number 395 030 844 Date Total number of issued shares Number ", "date_published": "2026-08-13T16:34:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "SNW"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SNW", "name": "Sanofi", "sentiment_url": "https://sharemaestro.com/sentiment/409d32ba-c809-4e5a-aaf2-cd377cff2a42/"}]}}, {"id": "source:5a0d5b0118aed9417b7f16d5981c04f347cdcc4923eab2e106061425e0ed31a4", "url": "https://finance.yahoo.com/markets/world-indices/articles/european-stocks-close-mixed-thursday-155457527.html", "external_url": "https://finance.yahoo.com/markets/world-indices/articles/european-stocks-close-mixed-thursday-155457527.html", "title": "European Stocks Close Mixed in Thursday Trading; UK GDP Growth Slows in Q2", "content_text": "The European stock markets closed mixed in Thursday trading as The Stoxx Europe edged 0.1% lower, Ge PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "date_published": "2026-08-13T15:54:57+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "LLY"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/6ac19f25-d335-40a8-b326-861b94ed8006/"}]}}, {"id": "source:42a629e691055a42ec13ef8bc6f0f3c3d31f7b2c7e8038507a15807a75e34ff2", "url": "https://finance.yahoo.com/healthcare/articles/market-chatter-novartis-wins-uk-153302721.html", "external_url": "https://finance.yahoo.com/healthcare/articles/market-chatter-novartis-wins-uk-153302721.html", "title": "Update: Market Chatter: Novartis Wins UK Court Challenge to Entresto Patent", "content_text": "(Updates with response from a Novartis spokesperson in the fourth and fifth paragraphs.)Novartis (NVS) defeated a bid by Accord Healthcare to invalidate its Entresto patent, with a UK court ruling that the patent and a related protection certificate remain valid, Reuters reported Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-13T15:33:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "NOT"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NOT", "name": "NOVARTIS AG                   N", "sentiment_url": "https://sharemaestro.com/sentiment/8d24fbcd-b8d4-4b17-95bc-a89fe4d19e2a/"}]}}, {"id": "source:33e32a55454fb0399fcd532ed23175ffd075d37280d0c841a24aff8a18065e15", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-higher-2026-guidance-litfulo-151241315.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizer-higher-2026-guidance-litfulo-151241315.html", "title": "How Pfizer\u2019s Higher 2026 Guidance And LITFULO Trial Results At Pfizer (PFE) Have Changed Its Investment Story", "content_text": "In early August 2026, Pfizer Inc. reported second-quarter results showing revenue of US$15,034 million and a net loss of US$248 million, alongside US$4.30 billion in non-cash intangible asset impairments and a modest increase in full-year 2026 revenue guidance to US$60.50\u2013US$62.50 billion. A key offsetting highlight was the positive Phase 3 data for Pfizer's autoimmune drug LITFULO in nonsegmental vitiligo, underlining the growing importance of its non-COVID portfolio and broader immunology and dermatology pipeline. We'll now explore how Pfizer's higher 2026 revenue guidance, backed by non-COV", "date_published": "2026-08-13T15:12:41+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b7ca93f2-2dc7-4008-a388-6f2d93608932/"}]}}, {"id": "source:ec826990d2c6b2707cb2345a499149ef75cc010896670e707947cc069f7f222f", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-151234003.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-151234003.html", "title": "Novo Nordisk (CPSE:NOVO B) Sees New Pressure In Weight Loss Drugs", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) faces fresh competition as the UK's MHRA approves Eli Lilly's oral weight loss therapy Foundayo for use in the country. The approval adds a non injectable option alongside Novo Nordisk's GLP 1 based obesity drugs and could affect demand patterns if Foundayo is adopted in public healthcare settings. In the US, Amazon Pharmacy launches a new Medicare weight loss drug program priced at $50 per month that will include Novo Nordisk an", "date_published": "2026-08-13T15:12:34+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "NOV", "LLY"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOV", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/99663662-e62d-4669-8f9e-ac0c78084f2f/"}, {"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/6ac19f25-d335-40a8-b326-861b94ed8006/"}]}}, {"id": "source:21cdd6efb4f006a77a1ccec8b3e58b1a3934172bb51c9e54a5a601ca9f190457", "url": "https://finance.yahoo.com/media-advertising/articles/advertising-research-foundation-announces-2026-150200996.html", "external_url": "https://finance.yahoo.com/media-advertising/articles/advertising-research-foundation-announces-2026-150200996.html", "title": "The Advertising Research Foundation Announces 2026 ARF David Ogilvy Awards Finalists", "content_text": "NEW YORK, Aug. 13, 2026 /PRNewswire/ -- The Advertising Research Foundation (ARF) today announced the finalists for the 2026 ARF David Ogilvy Awards, honoring excellence in research-driven advertising and marketing. For more than 30 years, the ARF David Ogilvy Awards have recognized campaigns that demonstrate how consumer insights and research can inspire creative work that delivers measurable business results. This year's finalists represent leading brands across categories including Automotive, B2B, Cultural Fluency, Financial Services & Insurance, Food & Beverage, Health & Personal Care, Be", "date_published": "2026-08-13T15:02:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b7ca93f2-2dc7-4008-a388-6f2d93608932/"}]}}, {"id": "source:1bf83bc90c892913c96d9159dc11f2436f52e3155ab02f2e8fc6269a170353e1", "url": "https://www.nasdaq.com/articles/noteworthy-etf-outflows-tqqq-adi-mrvl-gild", "external_url": "https://www.nasdaq.com/articles/noteworthy-etf-outflows-tqqq-adi-mrvl-gild", "title": "Noteworthy ETF Outflows: TQQQ, ADI, MRVL, GILD", "content_text": "Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro QQQ (Symbol: TQQQ) where we have detected an approximate $156.7 million dollar outflow -- that's a 0.4% decrease week over week (from 506,050,000 to 503,950,000). Among the largest underlying components of TQQQ, in trading today Analog Devices Inc (Symbol: ADI) is up about 0.8%, Marvell Technology Inc (Symbol: MRVL) is up about 4.9%, and Gilead Sciences Inc (Symbol: GILD) is up by about 1%. For a complete list of holdings, visit the TQQQ Holdings ", "date_published": "2026-08-13T14:49:26+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Market update", "GIS"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GIS", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e3c6982e-ae5c-4ff3-adc6-34eca37512f0/"}]}}, {"id": "source:db71b0b296aedbce1995a29b5568dcd4026f0c736ce1e90097a67b9907424050", "url": "https://finance.yahoo.com/healthcare/articles/cvs-health-enhances-direct-consumer-143000440.html", "external_url": "https://finance.yahoo.com/healthcare/articles/cvs-health-enhances-direct-consumer-143000440.html", "title": "CVS Health Enhances Its Direct-to-Consumer Weight Management Offerings To Improve Access, Affordability, Care and Support for GLP-1 Medications", "content_text": "WOONSOCKET, RI / ACCESS Newswire / August 13, 2026 / Originally published on CVS Health Company Newsroom CVS Pharmacy offers all FDA approved GLP-1s, whether through insurance or cash-pay options. New collaboration with Eli Lilly and Company will provide eligible Zepbound and Foundayo patients an additional access point at CVS Pharmacy through the CVS Health app MinuteClinic digital weight loss visits lowered to $29, the most affordable option in the market, available 24/7 Combines an online visit with a licensed clinician, same-day medication pickup at 9,000 local CVS Pharmacy locations, and ", "date_published": "2026-08-13T14:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLY"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/6ac19f25-d335-40a8-b326-861b94ed8006/"}]}}, {"id": "source:285cd116450d19c84ebc238b53aebf9d2f68170dd87757a5fed39d74f6c4c85b", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisks-glp-1-pill-142600733.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisks-glp-1-pill-142600733.html", "title": "Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?", "content_text": "Novo Nordisk NVO remains a dominant player in the GLP-1 market, marketing its semaglutide drugs Ozempic and Rybelsus for type II diabetes (T2D) and Wegovy for chronic weight management. However, the company's core franchise is facing mounting competitive pressure from Eli Lilly LLY, despite NVO delivering a better-than-expected second-quarter 2026 performance. NVO's reported second-quarter sales rose 3% to $12.21 billion (DKK 78.5 billion) at constant exchange rates (CER). More importantly, its key GLP-1 brands showed signs of slowing. Ozempic generated $4.88 billion (DKK 31.4 billion) in repo", "date_published": "2026-08-13T14:26:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLY"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/6ac19f25-d335-40a8-b326-861b94ed8006/"}]}}, {"id": "source:da0297559d651677418fbbf2281dc586889c01c0c9a0ba40b54c6abb3d366400", "url": "https://finance.yahoo.com/markets/stocks/articles/2-p-500-stocks-exciting-140500822.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/2-p-500-stocks-exciting-140500822.html", "title": "2 S&P 500 Stocks with Exciting Potential and 1 We Ignore", "content_text": "2 S&P 500 Stocks with Exciting Potential and 1 We Ignore The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition. Picking the right S&P 500 stocks requires more than just buying big names, and that's where StockStory comes in. That said, here are two S&P 500 stocks that could deliver good returns and one that may struggle. One Stock to Sell: Hartford (HIG) Market Cap: $38.23", "date_published": "2026-08-13T14:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLY"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/6ac19f25-d335-40a8-b326-861b94ed8006/"}]}}, {"id": "source:101ca26192ab6e98d81cd342a73465bb4ea3b94c3cf4262e0826f541a1f35522", "url": "https://finance.yahoo.com/healthcare/articles/keytruda-sustain-mercks-growth-second-140000696.html", "external_url": "https://finance.yahoo.com/healthcare/articles/keytruda-sustain-mercks-growth-second-140000696.html", "title": "Can Keytruda Sustain Merck's Growth in the Second Half of 2026?", "content_text": "Merck's MRK strong foothold in the oncology space is backed by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounts for more than 55% of the company's total pharmaceutical sales. In the United States, Keytruda is approved for 44 indications spanning 19 tumor types, along with two tumor-agnostic approvals as well as for many of these indications worldwide. Notably, more than 2,800 clinical studies are currently evaluating Keytruda across multiple cancer types and treatment settings. Keytruda, approved for several types of cancers, has played an instrumental role ", "date_published": "2026-08-13T14:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "RHO", "BRM"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "RHO", "name": "Roche Holding AG", "sentiment_url": "https://sharemaestro.com/sentiment/2a6f65e5-1771-4a10-b90e-9b8e1223008b/"}, {"symbol": "BRM", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/76da2cf7-50cc-4dc4-b51d-157448b7cb97/"}]}}, {"id": "source:680781d62dcbd5eeeeb19a08182cf19c2622f9db2db673e90b75e3356e08f20a", "url": "https://finance.yahoo.com/healthcare/articles/llys-foundayo-posts-98m-q2-134200240.html", "external_url": "https://finance.yahoo.com/healthcare/articles/llys-foundayo-posts-98m-q2-134200240.html", "title": "LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?", "content_text": "Eli Lilly and Company LLY announced second-quarter results on Aug. 5. Investors were keen to know the first sales numbers and initial launch uptake of Lilly's new once-daily oral GLP-1 pill, Foundayo (orforglipron) for treating obesity, which was launched in April. Foundayo (orforglipron) generated $98 million in sales in the second quarter, its first full quarter on the market. Lilly expects Foundayo to be a commercial game-changer for the company as oral pills are expected to be a more convenient alternative to the currently available once-weekly injectable obesity treatments like Lilly's Ze", "date_published": "2026-08-13T13:42:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLY"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/6ac19f25-d335-40a8-b326-861b94ed8006/"}]}}, {"id": "source:cb06f6881a4ca0938732efe5068ee1c6a1d658b8fcc1c0e0dcadc224181ff274", "url": "https://finance.yahoo.com/healthcare/articles/opko-health-expands-strategic-relationship-131500140.html", "external_url": "https://finance.yahoo.com/healthcare/articles/opko-health-expands-strategic-relationship-131500140.html", "title": "OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests", "content_text": "OPKO Health, Inc. Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through the issuance of an additional $125 million aggregate principal amount of senior secured notes. The newly issued notes are secured by OPKO's royalty interests arising under its mazdutide license agreement with Eli Lilly and Company and mature i", "date_published": "2026-08-13T13:15:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "LLY"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/6ac19f25-d335-40a8-b326-861b94ed8006/"}]}}, {"id": "source:ef9d3d7f9a3cac5d56dd9718d04368d61c876245a0e5064fb36dfc398fa75828", "url": "https://www.nasdaq.com/articles/ligand-lgnd-q2-2026-earnings-call-transcript", "external_url": "https://www.nasdaq.com/articles/ligand-lgnd-q2-2026-earnings-call-transcript", "title": "Ligand (LGND) Q2 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Head of Investor Relations - Melanie HermanChief Executive Officer - Todd DavisChief Financial Officer - Octavio EspinozaVice President of Portfolio Strategy and Investments - Lauren Hay TAKEAWAYS Total Revenue -- $63.7 million, representing a 34% increase driven primarily by royalty growth.Royalty Revenue -- $48.0 million, growing 32% year over year due to strong performance from Filspari, Ohtuvayre, and Zelsuvmi.Adjusted Diluted EPS -- $2.37, an increase of 48% from the prior year reflecting scalabil", "date_published": "2026-08-13T13:13:24+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "AMG"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "AMG", "name": "Amgen Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/168fd802-fccc-4e50-a2bc-bc539b6e35a1/"}]}}, {"id": "source:b2b30acb8c06b5f7976cf658d8db7cb75ef996188e43620f614f32c8afcad0e8", "url": "https://finance.yahoo.com/healthcare/articles/aimwellbio-publishes-investor-briefing-acquired-130000812.html", "external_url": "https://finance.yahoo.com/healthcare/articles/aimwellbio-publishes-investor-briefing-acquired-130000812.html", "title": "AimwellBio Publishes Investor Briefing on Acquired Trustr Intellectual Property Portfolio Valued at $10m Reinforcing Commitment to Transparency", "content_text": "Behavioral engagement technology carries documented institutional lineage spanning Oxford, the University of Vermont, Cornell, AMCP, and a Sanofi pilot program, as inventor Dr. Chris A. Jones joins AimwellBio's Board of Advisors and leads further expansion. MIAMI, FL / ACCESS Newswire / August 13, 2026 / Aimwell Partners Inc. (OTC:AIMN) - AimwellBio today announced the availability of a comprehensive investor briefing covering the recently acquired Trustr intellectual property portfolio. The briefing is available to current and prospective investors as part of the Company's commitment to provi", "date_published": "2026-08-13T13:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "SNW"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SNW", "name": "Sanofi", "sentiment_url": "https://sharemaestro.com/sentiment/409d32ba-c809-4e5a-aaf2-cd377cff2a42/"}]}}, {"id": "source:3b735e4b7d6de1b3802d4be91d33a8ae5f25622babda52dafd79d81fd27b4acd", "url": "https://finance.yahoo.com/technology/articles/priori-expands-client-advisory-board-130000660.html", "external_url": "https://finance.yahoo.com/technology/articles/priori-expands-client-advisory-board-130000660.html", "title": "Priori Expands Client Advisory Board with New Members from Fortune 500 Corporate Legal Departments", "content_text": "Priori Legal operations and legal department leaders from Mastercard, Meta, Google, Uber, General Motors, U.S. Bank, Capital One and more will help shape the future of outside counsel management NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Priori, the legal technology company modernizing outside counsel management and hiring, today announced the members of its 2026\u20132027 Client Advisory Board (CAB), a group of senior legal operations and legal department leaders who provide strategic guidance on the company's product roadmap and the evolving needs of modern in-house legal teams. The 2026\u20132027 CA", "date_published": "2026-08-13T13:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "BRM"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BRM", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/76da2cf7-50cc-4dc4-b51d-157448b7cb97/"}]}}, {"id": "source:abc8622d32621fa12aa741e3e18cc688963e7c916e85cf11b5df370c94aebe19", "url": "https://finance.yahoo.com/markets/stocks/articles/pfizer-ceo-buys-1-million-122046176.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/pfizer-ceo-buys-1-million-122046176.html", "title": "Pfizer CEO Buys $1 Million of Stock", "content_text": "This article first appeared on GuruFocus. Pfizer Inc. (PFE, Financials) The pharmaceutical giant earned a new vote of confidence from its top executive. Albert Bourla bought about $1 million worth of company stock. Bourla purchased 38,000 shares at $26.34 apiece, which increased his ownership interest to 429,172 shares.The reason people watch insider buying is that CEOs are already compensated very well based on how well the firm does, so buying shares on the open market is more interesting than receiving stock as part of a regular pay package.The decision comes as Pfizer also seeks to persuad", "date_published": "2026-08-13T12:20:46+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b7ca93f2-2dc7-4008-a388-6f2d93608932/"}]}}, {"id": "source:6a718becf991eeeaf34cd79c446bedd27ee9e3434e04d0e0d2465e2556e48a95", "url": "https://finance.yahoo.com/m/5ca00ec7-60e3-37e1-afbf-424b9fe2957d/this-healthcare-services.html", "external_url": "https://finance.yahoo.com/m/5ca00ec7-60e3-37e1-afbf-424b9fe2957d/this-healthcare-services.html", "title": "This Healthcare Services Stock Has 37% Upside", "content_text": "Well-known pharmaceutical companies such as Merck and Pfizer typically manage this complex process in house. Medpace Holdings which targets oncology, metabolic, cardiology, central nervous system, and anti-infective therapies, raised its 2026 revenue guidance on July\u2019s second-quarter conference call to a midpoint of $2.85 billion, corresponding to a year-over-year increase of 13%. Three months later, Medpace is in the pink: On the heels of second-quarter earnings, the stock is up 14%. Continue Reading", "date_published": "2026-08-13T12:01:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b7ca93f2-2dc7-4008-a388-6f2d93608932/"}]}}, {"id": "source:5005136220f6a61d846cd92aaeddf6255d5084564841ce404d79efb43a587664", "url": "https://finance.yahoo.com/healthcare/articles/atrium-therapeutics-earns-15-million-120000400.html", "external_url": "https://finance.yahoo.com/healthcare/articles/atrium-therapeutics-earns-15-million-120000400.html", "title": "Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration", "content_text": "SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (\"Atrium,\" \"Atrium Therapeutics\" or the \"Company\"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, today announced it has earned another $15 million milestone payment from Bristol Myers Squibb (NYSE: BMY) based on the successful delivery of a lead compound targeting an undisclosed cardiology indication under the Company's ongoing collaboration.Atrium Therapeutics logo \"Atrium's vision is to deliver treatments that address the underlying cause of serious heart disease, including ", "date_published": "2026-08-13T12:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "BRM"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BRM", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/76da2cf7-50cc-4dc4-b51d-157448b7cb97/"}]}}, {"id": "source:91092dc042f21d2049015aebad19a6bc538732ca2d40d3ea2ae4bb9e13730615", "url": "https://finance.yahoo.com/healthcare/articles/meiragtx-reports-second-quarter-2026-120000692.html", "external_url": "https://finance.yahoo.com/healthcare/articles/meiragtx-reports-second-quarter-2026-120000692.html", "title": "MeiraGTx Reports Second Quarter 2026 Financial and Operational Results", "content_text": "MeiraGTx Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) from Johnson & Johnson* (J&J) for $25 million Strengthened balance sheet with $100 million equity financing concurrent with the bota-vec acquisition Secured up to $400 million strategic investment from Ob", "date_published": "2026-08-13T12:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "JNJ"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/e87ae051-5953-43aa-97e5-132814dcdeea/"}]}}, {"id": "source:942c45952dd093cb334944b97dfa94e7e4b10082fe98774bfe152d7193ea3b67", "url": "https://finance.yahoo.com/markets/stocks/articles/big-tech-drives-credit-risk-103014617.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/big-tech-drives-credit-risk-103014617.html", "title": "Big Tech Drives Up Credit Risk for Safe Firms With No AI Links", "content_text": "(Bloomberg) -- As a flood of debt sales by US tech companies ripples through the credit market, it seems to be triggering an inadvertent rise in risk metrics for some of the world's safest firms. Most Read from Bloomberg Walter Sells Lakers, Seeks More Cash to Pay Loans Amid DOJ Probe Phoebe Gates Knew Phia Shopping App Took Credit for Sales It Didn't Drive Trump Seeks Immediate Halt to Judge's Penalties in IRS Case Anthropic Said in Talks to Buy Startup Decart for $6 Billion Trump Weighs Call for Capital Gains Tax Cuts as Midterm Boost Strategists at BNP Paribas SA say these moves are a knock", "date_published": "2026-08-13T10:30:14+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Balance sheet", "SNW"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SNW", "name": "Sanofi", "sentiment_url": "https://sharemaestro.com/sentiment/409d32ba-c809-4e5a-aaf2-cd377cff2a42/"}]}}, {"id": "source:1fb430f4d1b71b75f67c6b22999fe9bcfcc63d54812fb79c7524b788dcf10acc", "url": "https://finance.yahoo.com/markets/stocks/articles/invesco-dividend-achievers-etf-pfm-102001482.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/invesco-dividend-achievers-etf-pfm-102001482.html", "title": "Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar?", "content_text": "Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the Invesco Dividend Achievers ETF (PFM) is a passively managed exchange traded fund launched on September 15, 2005. The fund is sponsored by Invesco. It has amassed assets over $812.25 million, making it one of the average sized ETFs attempting to match the Large Cap Value segment of the US equity market. Why Large Cap Value Large cap companies usually have a market capitalization above $10 billion. Considered a more stable option, large cap companies boast more predictable cash flows and are less volat", "date_published": "2026-08-13T10:20:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LLY"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/6ac19f25-d335-40a8-b326-861b94ed8006/"}]}}, {"id": "source:79ac6a4212879c1730f4d9d7d98c7f0bb6fab689172f414cdbb637101d7d0624", "url": "https://finance.yahoo.com/healthcare/articles/why-gilead-sciences-gild-back-091117191.html", "external_url": "https://finance.yahoo.com/healthcare/articles/why-gilead-sciences-gild-back-091117191.html", "title": "Why Gilead Sciences (GILD) Is Back In The Spotlight", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences (GILD) is back in focus after announcing a collaboration with Nucleai that applies AI powered tissue analytics to its antibody drug conjugate programs, with the goal of speeding biomarker discovery across its oncology pipeline. See our latest analysis for Gilead Sciences. At a share price of $135.87, Gilead Sciences has posted an 11.74% year to date share price return and a 16.04% total shareholder return over the past year. Longer term total shareholder retur", "date_published": "2026-08-13T09:11:17+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "GIS"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GIS", "name": "Gilead Sciences, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/e3c6982e-ae5c-4ff3-adc6-34eca37512f0/"}]}}, {"id": "source:7206656e228d9cce183dd4204f56b18aff380db1192fae1fa1e27eccaf0b234f", "url": "https://finance.yahoo.com/healthcare/articles/amgen-q2-earnings-call-top-080500663.html", "external_url": "https://finance.yahoo.com/healthcare/articles/amgen-q2-earnings-call-top-080500663.html", "title": "Amgen\u2019s Q2 Earnings Call: Our Top 5 Analyst Questions", "content_text": "Amgen's Q2 Earnings Call: Our Top 5 Analyst Questions Amgen's second quarter results reflected broad-based portfolio momentum, with management crediting double-digit growth in key products like Repatha, EVENITY, and TEZSPIRE for the company's outperformance versus Wall Street estimates. CEO Robert Bradway highlighted that 22 products achieved double-digit sales growth, and 17 products annualized over $1 billion in sales, noting, \"Our strong results were driven by the breadth and depth of our portfolio and once again demonstrate our ability to grow through patent expirations and increased compe", "date_published": "2026-08-13T08:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "AMG"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "AMG", "name": "Amgen Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/168fd802-fccc-4e50-a2bc-bc539b6e35a1/"}]}}, {"id": "source:a376539870cb49b24c911d1e53cfe932f9e1e258e2dfb5e05c41dcfaf5f2f030", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQWXBudlBMWVZ5SzNsTGFaazdYWTNTSU12R1R2UndEVWt0eVNiWF9IV01tWHJJTFdnX3QzX1phTk1LYU1pY0ZQVjZidktIWXZNOEpHV2hpVnQ1bG1zU0I1R0lnSTNaWkxfZ0plYkp5WXM4RldlcWNvY29yYzAwUGRmaWJYVjJMVU9HcFpKSnRXeU5WZjI3b2dsUmRhRVNQd2JHSElmc3dNU3MzWTVPNXZHZ2o5c1NmYXhLMHVlSFhkc3lWQ1lIeXQybmxETQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQWXBudlBMWVZ5SzNsTGFaazdYWTNTSU12R1R2UndEVWt0eVNiWF9IV01tWHJJTFdnX3QzX1phTk1LYU1pY0ZQVjZidktIWXZNOEpHV2hpVnQ1bG1zU0I1R0lnSTNaWkxfZ0plYkp5WXM4RldlcWNvY29yYzAwUGRmaWJYVjJMVU9HcFpKSnRXeU5WZjI3b2dsUmRhRVNQd2JHSElmc3dNU3MzWTVPNXZHZ2o5c1NmYXhLMHVlSFhkc3lWQ1lIeXQybmxETQ?oc=5", "title": "Die Bristol-Myers-Squibb-Aktie steigt nach Konsensst\u00e4rke und solider Dividendenrendite", "content_text": "Die Bristol-Myers-Squibb-Aktie steigt nach Konsensst\u00e4rke und solider Dividendenrendite", "date_published": "2026-08-13T08:03:49+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Market update", "BRM"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BRM", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/76da2cf7-50cc-4dc4-b51d-157448b7cb97/"}]}}, {"id": "source:8ceae936bfaa25b84dea738fca41d3ad32bb6dd531005051c8730946393ccee7", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQTzdmdmxpVVlPMjVTbW5wWEJHRl8xVHlJMURuV3lTVGJ2UnJuNzhNc25mRXVkY2p2bElDU3NNS2VtQzlIcEFYeXZ5WW1XZFBmdW1BOHhXbkRNZnRoV2FjeVY4UTctcEZPSzRiTENBZzNHRDhvOEVicjZpYnR1eXZZdUdmTXUtU3FPa2RjdXJFLTNuT2ZyVHZ3YVk5Qm5SNVRYV3Y0dm9hUmozdlIwcUZsNEkyYjZtNHVvTkl3QzdZUFdHdVFkUDZWSTEzQzFoRVU?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxQTzdmdmxpVVlPMjVTbW5wWEJHRl8xVHlJMURuV3lTVGJ2UnJuNzhNc25mRXVkY2p2bElDU3NNS2VtQzlIcEFYeXZ5WW1XZFBmdW1BOHhXbkRNZnRoV2FjeVY4UTctcEZPSzRiTENBZzNHRDhvOEVicjZpYnR1eXZZdUdmTXUtU3FPa2RjdXJFLTNuT2ZyVHZ3YVk5Qm5SNVRYV3Y0dm9hUmozdlIwcUZsNEkyYjZtNHVvTkl3QzdZUFdHdVFkUDZWSTEzQzFoRVU?oc=5", "title": "Die Sanofi-Aktie legt nach starken Q2-2026-Zahlen und erh\u00f6hter Prognose zu", "content_text": "Die Sanofi-Aktie legt nach starken Q2-2026-Zahlen und erh\u00f6hter Prognose zu", "date_published": "2026-08-13T07:22:10+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Market update", "SNW"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SNW", "name": "Sanofi", "sentiment_url": "https://sharemaestro.com/sentiment/409d32ba-c809-4e5a-aaf2-cd377cff2a42/"}]}}, {"id": "source:5c3175630e88f5bc7762b7912b48c5c2bb9979bfb25b28db4bab7aa1d85378b1", "url": "https://finance.yahoo.com/healthcare/articles/spero-therapeutics-inc-spro-q2-050124333.html", "external_url": "https://finance.yahoo.com/healthcare/articles/spero-therapeutics-inc-spro-q2-050124333.html", "title": "Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ...", "content_text": "This article first appeared on GuruFocus. Cash and Cash Equivalents: $50.8 million as of June 30, 2026, excluding net proceeds from the July 2026 royalty financing. Revenue: No revenue for Q2 2026, compared to $14.2 million in Q2 2025, primarily due to prior collaboration revenue from Pfizer and GSK being fully realized. R&D Expenses: $3.4 million in Q2 2026, down from $10.7 million in Q2 2025, due to reduced clinical activity following the early completion of the Utebzi Phase 3 trial. G&A Expenses: $6.5 million in Q2 2026, up from $5.9 million in Q2 2025, driven by higher business development", "date_published": "2026-08-13T05:01:24+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PFE"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PFE", "name": "Pfizer Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/b7ca93f2-2dc7-4008-a388-6f2d93608932/"}]}}]}